secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alto Neuroscience, Inc. (ANRO)
CIK:        0001999480
Form:       8-K
Filed at:   2026-08-12T20:14:32+00:00
Accession:  0001999480-26-000022
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alto Neuroscience Q2 net loss $27.6M; expands ALTO-207 with Phase 3 monotherapy trial
--------------------------------------------------------------------------------

- Net loss $27.6M in Q2 2026 vs $17.7M year-ago; R&D expenses $22.1M vs $13.1M.
- July 2026 offering raised ~$100M gross; pro forma cash ~$338M, runway through 2030.
- ALTO-207 Phase 3 monotherapy TRD trial added; PACE-2 Phase 3 adjunctive to start early 2027; PACE-1 Phase 2b topline 2H 2027.
- Nature Medicine PRIME-PRAXOL: pramipexole reduced anhedonia (SHAPS p=0.006, Hedges' g=0.62) in MDD/bipolar depression.
- ALTO-300 Phase 2b MDD topline 1H 2027; ALTO-100 Phase 2b BPD topline mid-2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1999480/000199948026000022/0001999480-26-000022-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1999480/000199948026000022/alto-20260812.htm
  HTML page:      https://secwatch.observer/filing/0001999480-26-000022

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer